Eli Lilly and Company $LLY is Banque Transatlantique SA’s 10th Largest Position

Banque Transatlantique SA cut its stake in Eli Lilly and Company (NYSE:LLY) by 27.5% in the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 147,715 shares of the company’s stock after selling 56,022 shares during the period. Eli Lilly and Company accounts for about 3.2% of Banque Transatlantique SA’s portfolio, making the stock its 10th largest position. Banque Transatlantique SA’s holdings in Eli Lilly and Company were worth $115,572,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds have also bought and sold shares of LLY. Blue Capital Inc. purchased a new position in Eli Lilly and Company in the 2nd quarter worth $3,024,000. BlueCrest Capital Management Ltd purchased a new stake in Eli Lilly and Company during the 2nd quarter valued at about $7,278,000. Brevan Howard Capital Management LP increased its holdings in shares of Eli Lilly and Company by 1,283.8% in the second quarter. Brevan Howard Capital Management LP now owns 20,176 shares of the company’s stock valued at $15,728,000 after purchasing an additional 18,718 shares during the period. Bamco Inc. NY increased its holdings in shares of Eli Lilly and Company by 200.3% in the second quarter. Bamco Inc. NY now owns 98,639 shares of the company’s stock valued at $76,892,000 after purchasing an additional 65,795 shares during the period. Finally, Adage Capital Partners GP L.L.C. raised its stake in shares of Eli Lilly and Company by 13.5% in the second quarter. Adage Capital Partners GP L.L.C. now owns 841,810 shares of the company’s stock worth $656,216,000 after purchasing an additional 100,088 shares during the last quarter. Institutional investors and hedge funds own 82.53% of the company’s stock.

Wall Street Analyst Weigh In

LLY has been the topic of a number of recent research reports. Cantor Fitzgerald reiterated an “overweight” rating on shares of Eli Lilly and Company in a research report on Monday, December 1st. Hsbc Global Res upgraded shares of Eli Lilly and Company from a “moderate sell” rating to a “hold” rating in a research note on Wednesday, August 27th. HSBC reaffirmed a “hold” rating and issued a $1,070.00 price objective on shares of Eli Lilly and Company in a report on Wednesday. Wolfe Research raised their target price on shares of Eli Lilly and Company from $1,050.00 to $1,250.00 and gave the stock an “outperform” rating in a report on Wednesday, December 3rd. Finally, CICC Research upped their price target on shares of Eli Lilly and Company from $801.00 to $1,060.00 and gave the company a “neutral” rating in a report on Thursday, November 13th. Three research analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and six have assigned a Hold rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $1,109.24.

Eli Lilly and Company Stock Up 1.8%

Eli Lilly and Company stock opened at $1,027.68 on Friday. The company has a debt-to-equity ratio of 1.71, a current ratio of 1.55 and a quick ratio of 1.24. The stock has a market capitalization of $971.55 billion, a PE ratio of 50.28, a price-to-earnings-growth ratio of 1.12 and a beta of 0.37. The business has a 50 day simple moving average of $939.47 and a 200-day simple moving average of $818.98. Eli Lilly and Company has a 12 month low of $623.78 and a 12 month high of $1,111.99.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings results on Thursday, October 30th. The company reported $7.02 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $6.42 by $0.60. The firm had revenue of $17.60 billion for the quarter, compared to analysts’ expectations of $16.09 billion. Eli Lilly and Company had a net margin of 30.99% and a return on equity of 109.52%. The firm’s revenue for the quarter was up 53.9% compared to the same quarter last year. During the same quarter last year, the company earned $1.18 EPS. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. On average, analysts anticipate that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Eli Lilly and Company Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, March 10th. Stockholders of record on Friday, February 13th will be paid a dividend of $1.73 per share. This is an increase from Eli Lilly and Company’s previous quarterly dividend of $1.50. This represents a $6.92 dividend on an annualized basis and a dividend yield of 0.7%. The ex-dividend date of this dividend is Friday, February 13th. Eli Lilly and Company’s dividend payout ratio is presently 29.35%.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.